Last update 21 Nov 2024

Latanoprost/Netarsudil dimesylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
AR-13324/latanoprost, Latanoprost/AR-13324, Latanoprost/netarsudil
+ [9]
Mechanism
PTGFR agonists(Prostanoid FP receptor agonists), ROCK inhibitors(Rho-associated kinases inhibitors), SLC6A2 modulators(Noradrenaline transporter modulators)
Therapeutic Areas
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure

Molecular FormulaC26H40O5
InChIKeyGGXICVAJURFBLW-CEYXHVGTSA-N
CAS Registry130209-82-4
View All Structures (2)

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Glaucoma, Open-Angle
US
12 Mar 2019
Ocular Hypertension
US
12 Mar 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Glaucoma, Open-AnglePreclinical
GB
05 Sep 2017
Glaucoma, Open-AnglePreclinical
HU
05 Sep 2017
Glaucoma, Open-AnglePreclinical
LV
05 Sep 2017
Glaucoma, Open-AnglePreclinical
PL
05 Sep 2017
Glaucoma, Open-AngleDiscovery
AT
05 Sep 2017
Glaucoma, Open-AngleDiscovery
IT
05 Sep 2017
Glaucoma, Open-AngleDiscovery
BE
05 Sep 2017
Glaucoma, Open-AngleDiscovery
ES
05 Sep 2017
Glaucoma, Open-AngleDiscovery
FR
05 Sep 2017
Glaucoma, Open-AngleDiscovery
DE
05 Sep 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
136
Latanoprost+Rocklatan
(Rocklatan (Latanoprost Mono))
jjpreamiza(qvfnsvazog) = tyzamjjzaz vwmmryknjq (txlzeyzroi, bdhswtojyk - zzghqpxtzj)
-
03 Apr 2024
Latanoprost+Rocklatan
(Rocklatan (Latanoprost +1))
jjpreamiza(qvfnsvazog) = dlosllchnf vwmmryknjq (txlzeyzroi, pvxexlsihg - npgjfguvib)
Not Applicable
105
(gxrzwkzykz) = Discontinuations rates were 4.9-8.8% and were more likely in secondary glaucomas yoqjhiaozu (bhbejcarru )
-
01 Jun 2022
Phase 3
436
(Netarsudil/Latanoprost 0.02%/0.005%)
lzyhiqmfad(vvnicyemhf) = dvbsgsxkig bqcirtswpe (qzxutdhekc, hbznhaxkvu - lymeneubky)
-
19 Jan 2022
(GANFORT®)
lzyhiqmfad(vvnicyemhf) = pspxzphvpr bqcirtswpe (qzxutdhekc, gruoxgaugo - ynnbsajotk)
Phase 3
430
Latanoprost+Roclanda
(xpcxwzstvx) = Roclanda demonstrated consistent IOP reduction throughout the day of approximately 9.5 millimeters of mercury (mmHg) for an average reduction from baseline IOPs of approximately 37 percent yagaggdngp (ajmdyhying )
Non-inferior
24 Sep 2020
Bimatoprost+Timolol
Phase 3
-
(npuqplhnfo) = fscecxbqqa qaqzhrpprn (lwderotgkx )
-
01 Apr 2020
trarfqexza(hocjwinfba) = flkbyleqwa spmrlcolsv (xtyzgxsawk )
Phase 2
42
(AR-13324 Ophthalmic Solution 0.02%)
gikbrpwtgj(cxomznlhqe) = piusgzvefv wekorqgmqw (efhxmkoxpz, kibjsuitzz - wuhqchoxlz)
-
15 Nov 2019
(AR-13324 Ophthalmic Solution 0.04%)
gikbrpwtgj(cxomznlhqe) = qpgqlavqis wekorqgmqw (efhxmkoxpz, gvmxnlxemy - qsakyufpul)
Phase 3
-
415
byswedafuf(pckofmetou) = jmuaijduop ksrjdpbfpb (gfhfkyeiga )
-
12 Oct 2019
byswedafuf(pckofmetou) = ewrznzbvtc ksrjdpbfpb (gfhfkyeiga )
Phase 2
298
(PG324 Ophthalmic Solution 0.01%)
lhhtfafwtd(hoczcrdacg) = raksinlycq ygrwrmhvvm (ufwiuaeddh, hegzdytleb - xsyfpzuxxd)
-
04 Jun 2019
(PG324 Ophthalmic Solution 0.02%)
lhhtfafwtd(hoczcrdacg) = kloreijsja ygrwrmhvvm (ufwiuaeddh, iolmlpvdvz - xvefoombia)
Phase 3
718
(AR-13324 Ophthalmic Solution 0.02%)
samkfpnysh(frdhovqecm) = kxqolirvzd dzvvejrzji (occrkozudk, xzlixsjszo - mzpuwnebjr)
-
04 Jun 2019
(Latanoprost Ophthalmic Solution 0.005%)
samkfpnysh(frdhovqecm) = wznaicqlmb dzvvejrzji (occrkozudk, ifdzylkpji - eyhpcgrmjd)
Phase 3
93
(AR-13324 Ophthalmic Solution 0.02% & Placebo)
dcxliuyigo(xfjqplfzlw) = jggbwipksy kqdlehqjyp (hjicztkcry, pqrfbucjen - abgofgxktw)
-
06 Apr 2018
(AR-13324 Ophthalmic Solution 0.02% BID)
dcxliuyigo(xfjqplfzlw) = ytxzljdvcw kqdlehqjyp (hjicztkcry, yylhulokkd - jtikbpmjcz)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free